

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Julia Ann Straub, Howard Bernstein, Donald E. Chickering III, Sarwat Khattak

and Greg Randall

Serial No.:

09/706,045

Art Unit:

1617

Filed:

November 3, 2000

Examiner:

Not Yet Assigned

For:

POROUS DRUG MATRICES AND METHODS FOR

MANUFACTURE THEREOF

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449 and a copy of the document cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 50-1868.

U.S. Patents

Number 5,762,961 Issue Date 06-09-1998 Patentee Roser et al. Class/Subclass

424/464

U.S.S.N.:

09/706,045

Filed:

November 3, 2000 SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Remarks

his statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Patrea L. Pabst

Reg! No. 31,284

Dated: October 18, 2001

HOLLAND & KNIGHT LLP One Atlantic Center 1201 West Peachtree Street, N.E. **Suite 2000** Atlanta, Georgia 30309-3400 404-817-8500 FAX 404-817-0470 www.hklaw.com

U.S.S.N.:

09/706,045

Filed:

November 3, 2000

SUPPLEMENTAL INFORMATION DISSLOSURE STATEMENT

N 0 9 2002

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

October 18, 2001

3